Educational Development (NASDAQ:EDUC) reported quarterly sales of $30.27 million which missed the analyst consensus estimate of $46.00 million by 34.20 percent. This is a 32.90 percent decrease over sales of $45.11 million the same period last year.
Athersys Reports Interim Analysis Results Of MASTERS-2 Clinical Study With MultiStem In Ischemic Stroke, Signs Memorandum Of Understanding For Global ARDS License With Healios; Includes $1.5M To $4.5M Near Term Payments Plus Up To $150M In Milestones
The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestonesAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care
